Gran® (filgrastim) & Peglasta® (pegfilgrastim): Risk of capillary leak syndrome in patients with cancer (filgastrim & pegfilgastrim) and in healthy donors (filgastrim only)

Kadar pengguna: 1 / 5

bintang aktifBintang tidak aktifBintang tidak aktifBintang tidak aktifBintang tidak aktif

Date: 06 August 2014

Description: The NPCB would like to alert healthcare professionals that cases of capillary leak syndrome (CLS) have been reported in recipients of filgrastim including patients undergoing chemotherapy and a healthy donor undergoing peripheral blood progenitor cell mobilisation. CLS has also been reported in recipients of pegfilgrastim undergoing chemotherapy. Patients and healthy donors should be monitored closely for CLS symptoms such as oedema, difficulty breathing, and tiredness. For further details, please refer to the Direct Healthcare Professional Communication (DHPC) issued by SmartMedicine Sdn. Bhd. in agreement with NPCB.

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti (Jalan Profesor Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.
  • Email:
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Rabu 17 Ogos 2022, 09:53:12.
© Copyright 2022 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA


Choose Your Language